Suppr超能文献

使用一种简单可靠的体外寄生虫活力快速测定法来鉴定快速杀寄生虫的抗疟药物。

Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay.

作者信息

Linares María, Viera Sara, Crespo Benigno, Franco Virginia, Gómez-Lorenzo María G, Jiménez-Díaz María Belén, Angulo-Barturen Íñigo, Sanz Laura María, Gamo Francisco-Javier

机构信息

R&D Alternative Discovery and Development, Diseases of the Developing World, GlaxoSmithKline, 28760 Tres Cantos, Madrid, Spain.

出版信息

Malar J. 2015 Nov 5;14:441. doi: 10.1186/s12936-015-0962-2.

Abstract

BACKGROUND

The emergence of Plasmodium falciparum resistance to artemisinins threatens to undermine the effectiveness of artemisinin-based combination anti-malarial therapy. Developing suitable drugs to replace artemisinins requires the identification of new compounds that display rapid parasite killing kinetics. However, no current methods fully meet the requirements to screen large compound libraries for candidates with such properties. This study describes the development and validation of an in vitro parasite viability fast assay for identifying rapidly parasiticidal anti-malarial drugs.

METHODS

Parasite killing kinetics were determined by first culturing unlabelled erythrocytes with P. falciparum in the presence of anti-malarial drugs for 24 or 48 h. After removing the drug, samples were added to erythrocytes pre-labelled with intracellular dye to allow their subsequent identification. The ability of viable parasites to re-establish infection in labelled erythrocytes could then be detected by two-colour flow cytometry after tagging of parasite DNA. Thus, double-stained erythrocytes (with the pre-labelled intracellular dye and the parasite DNA dye) result only after establishment of new infections by surviving parasites. The capacity of the test anti-malarial drugs to eliminate viable parasites within 24 or 48 h could, therefore, be determined.

RESULTS

The parasite viability fast assay could be completed within 48 h following drug treatment and distinguished between rapidly parasiticidal anti-malarial drugs versus those acting more slowly. The assay was validated against ten standard anti-malarial agents with known properties and results correlated well with established methods. An abbreviated assay, suitable for adaption to medium-high throughput screening, was validated and applied against a set of 20 compounds retrieved from the publically available Medicines for Malaria Venture 'Malaria Box'.

CONCLUSION

The quantification of new infections to determine parasite viability offers important advantages over existing methods, and is amenable to medium-high throughput screening. In particular, the parasite viability fast assay allows discrimination of rapidly parasiticidal anti-malarial candidates.

摘要

背景

恶性疟原虫对青蒿素产生耐药性,这可能会削弱以青蒿素为基础的联合抗疟疗法的有效性。开发合适的药物来替代青蒿素需要鉴定出具有快速杀灭寄生虫动力学的新化合物。然而,目前尚无方法能完全满足从大型化合物库中筛选具有此类特性的候选化合物的要求。本研究描述了一种用于鉴定快速杀疟抗疟药物的体外寄生虫活力快速检测方法的开发与验证。

方法

通过首先在抗疟药物存在的情况下,将未标记的红细胞与恶性疟原虫培养24或48小时来确定寄生虫杀灭动力学。去除药物后,将样品加入预先用细胞内染料标记的红细胞中,以便随后进行鉴定。在对寄生虫DNA进行标记后,通过双色流式细胞术可以检测存活寄生虫在标记红细胞中重新建立感染的能力。因此,只有在存活寄生虫建立新感染后才会出现双染红细胞(同时带有预先标记的细胞内染料和寄生虫DNA染料)。因此,可以确定受试抗疟药物在24或48小时内消除存活寄生虫的能力。

结果

寄生虫活力快速检测可在药物处理后48小时内完成,并能区分快速杀疟的抗疟药物和作用较慢的药物。该检测方法针对十种具有已知特性的标准抗疟药物进行了验证,结果与既定方法相关性良好。一种适用于中高通量筛选的简化检测方法得到了验证,并应用于从公开可用的疟疾药物风险投资公司“疟疾药盒”中获取的一组20种化合物。

结论

通过对新感染进行定量以确定寄生虫活力,与现有方法相比具有重要优势,并且适用于中高通量筛选。特别是,寄生虫活力快速检测能够区分快速杀疟的抗疟候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a288/4635989/a50c2c1df9dd/12936_2015_962_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验